세계의 유방암 치료제 시장(2023-2030년)

Market Overview

The Global Breast Cancer Drugs Market reached US$ 28.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 57.1 billion by 2030. The Global Breast Cancer Drugs Market is expected to exhibit a CAGR of 9.2% during the forecast period 2023-2030. The increasing demand for discovering novel therapies and optimizing existing treatments are driving up demand for breast cancer drug market trends.

The Breast cancer drugs market is witnessing significant growth and is expected to continue expanding in the coming years. The rising awareness about breast cancer, improved screening programs, and early detection initiatives are leading to higher diagnosis rates, thereby increasing the demand for effective treatment options, including breast cancer drugs.

Additionally, advancements in genomic profiling and personalized medicine approaches are driving the development of targeted therapies, which are gaining prominence in the market due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy.

Market Dynamics

Increasing Demand for Innovations and New Drug Approvals Drive the Growth of the Breast Cancer Drugs Market

As the number of breast cancer patients rises, there is a continuous need for more effective and targeted therapies to combat breast cancer, one of the most common and potentially life-threatening cancers worldwide. As a result, pharmaceutical companies are investing heavily in research and development to introduce novel drugs and treatment approaches.

For instance, on February 03, 2023, Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of breast cancer and announced that the Trodelvy is now also recommended as a Category 1, preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network (NCCN) as defined in the Clinical Practice Guidelines in Oncology (NCCN Guidelines)

The market's growth is fueled by the pursuit of innovative solutions that can improve patient outcomes and quality of life. Advances in molecular biology, genomics, and personalized medicine have led to the discovery of specific molecular targets and pathways in breast cancer cells. This knowledge enhanced the way for the development of targeted therapies that selectively act on these targets, delivering more precise and effective treatments.

Rising Awareness and Early Detection Also Drive the Growth of the Breast Cancer Drugs Market

As awareness about breast cancer grows, more individuals are encouraged to undergo regular screenings and seek medical attention at the earliest signs or symptoms. Early detection enables timely diagnosis, which leads to improved treatment outcomes and increased survival rates. With a larger number of breast cancer cases being detected in the early stages, the demand for effective treatment options, including breast cancer drugs, rises.

For instance, on April 03, 2023, Ambuja Cements, the cement and building material company of Adani Cement and part of Adani Group, through its CSR arm launched a Cancer Awareness and Education program in collaboration with the Association of Breast Surgery (ABS), UK along with its counterpart Association of Breast Surgeons in India (ABSI) and Tata Cancer Care Program, in Chandrapur, Maharashtra to educate communities.

The emphasis on early detection is supported by advancements in medical imaging technologies and diagnostic techniques. Improved screening methods, such as mammography, ultrasound, and magnetic resonance imaging (MRI), enable the identification of breast cancer at earlier stages when the disease is localized and more amenable to treatment. This shift towards early detection not only improves patient outcomes but also drives the demand for appropriate therapies, including breast cancer drugs.

The High Cost of Drugs will Hamper the Growth of the Market.

The high cost of breast cancer drugs can create affordability issues for patients, particularly those without adequate insurance coverage or limited financial resources. The out-of-pocket expenses associated with these drugs can be burdensome, making them inaccessible to a significant portion of the population. Limited access to affordable breast cancer drugs can impact treatment adherence and patient outcomes, thereby hampering market growth.

Healthcare systems and payers face challenges in managing the high costs of breast cancer drugs. The budgetary constraints of healthcare systems can lead to cost containment measures, including reimbursement limitations, formulary restrictions, and price negotiations. These measures can affect the market dynamics and limit the utilization of expensive drugs, thus impeding market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the Breast Cancer Drugs Market. The pandemic led to a diversion of healthcare resources and attention towards managing COVID-19 cases, resulting in disruptions in routine healthcare services, including breast cancer screenings, diagnosis, and treatment. Many non-urgent medical procedures, including cancer surgeries and treatments, were delayed or postponed, affecting the overall demand for breast cancer drugs.

Clinical trials for breast cancer drugs were significantly affected by the pandemic. Many trials were paused, delayed, or modified to ensure patient safety and comply with infection control measures. The slowdown in clinical trial activities hindered the progress of drug development and the introduction of new therapies into the market.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to impact the Global Breast Cancer Drugs market moderately. The conflict may affect international collaborations in clinical trials and research efforts t. Collaborative studies involving researchers, institutions, and patients from Russia and Ukraine faced disruptions, leading to delays in developing new breast cancer drugs and limiting the expansion of the market globally.

Segment Analysis

The Global Breast Cancer Drugs Market is segmented based on cancer type, therapy, distribution channel, and region.

Targeted Therapy from the Therapy Segment Accounts for 47.4% of the Breast Cancer Drugs Market Share

Targeted therapy specifically focuses on cancer cells by identifying and attacking specific molecular targets involved in the growth and spread of cancer. Compared to traditional chemotherapy, targeted therapies offer the potential for more effective and precise treatments with reduced toxicity and side effects.

Targeted therapy drugs are designed to inhibit or block specific proteins or pathways crucial for cancer cells' growth and survival. These drugs can be classified into various categories, including monoclonal antibodies, tyrosine kinase inhibitors, hormone receptor blockers, and poly (ADP-ribose) polymerase (PARP) inhibitors. They are often used in combination with other treatment modalities, such as chemotherapy or radiation therapy, to enhance the overall effectiveness of the treatment.

For instance, on August 05, 2022, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is the first approved targeted therapy for patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.

Geographical Analysis

North America Accounted for Approximately 39.8% of the Market Share in 2022, Owing to the Favourable Reimbursement Policies and Advanced Healthcare Infrastructure.

North America, particularly the United States, benefits from a well-established healthcare system with advanced medical facilities, leading research institutions, and a robust pharmaceutical industry. The region has a strong focus on cancer research and development, leading to the availability of a wide range of breast cancer drugs. The advanced healthcare infrastructure ensures timely diagnosis, access to advanced treatment options, and comprehensive care for breast cancer patients.

Moreover, favorable reimbursement policies in North America contribute to the growth of the market. Adequate reimbursement for breast cancer drugs enables patients to access these treatments without significant financial burden. Health insurance coverage, both public and private, plays a crucial role in facilitating patient access to expensive cancer drugs, ensuring a larger patient population can benefit from the available treatment options.

Competitive Landscape

The major global players in the breast cancer drugs market include: Novartis AG, F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eli Lilly and Company, AstraZeneca, Merck & Co., Inc., Biocon Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, and Onyx Pharmaceuticals Inc.

Why Purchase the Report?

• To visualize the Global Breast Cancer Drugs Market segmentation based on cancer type, therapy, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of breast cancer drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Breast Cancer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Cancer Type
• 3.2. Snippet by Therapy
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Innovations and New Drug Approvals
    • 4.1.1.2. Rising Awareness and Early Detection
  • 4.1.2. Restraints
    • 4.1.2.1. The High Cost of Drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological Advancements in Breast Cancer Drugs
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Cancer Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 7.1.2. Market Attractiveness Index, By Cancer Type
• 7.2. Metastatic Breast Cancer *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Triple Negative Breast Cancer
• 7.4. Inflammatory Breast Cancer
• 7.5. Others

8. By Therapy

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 8.1.2. Market Attractiveness Index, By Therapy
• 8.2. Targeted Therapy *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Chemotherapy
• 8.4. Immunotherapy
• 8.5. Hormonal Therapy
• 8.6. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Novartis AG *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. F. Hoffmann-La Roche Ltd.
• 12.3. AbbVie, Inc.
• 12.4. Eli Lilly and Company
• 12.5. AstraZeneca
• 12.6. Merck & Co., Inc.
• 12.7. Biocon Genzyme Corporation
• 12.8. MacroGenics Inc.
• 12.9. Janssen Global Services LLC
• 12.10. Onyx Pharmaceuticals Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us